share_log

Needham Maintains Buy on Conmed, Lowers Price Target to $119

Benzinga ·  Oct 26, 2023 05:33

Needham analyst Mike Matson maintains Conmed (NYSE:CNMD) with a Buy and lowers the price target from $140 to $119.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment